Literature DB >> 9109049

Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers.

M Ramaswamy1, X Zhang, H M Burt, K M Wasan.   

Abstract

Amphiphilic diblock copolymer poly (D,L-lactide)-block-methoxy polyethylene glycol was synthesized, and paclitaxel (Taxol) was incorporated into this copolymer above its critical micelle concentration (cmc), resulting in the formation of polymeric micellar paclitaxel (PMT). Free paclitaxel dissolved in acetonitrile (TAX) and PMT, at 10 micrograms of paclitaxel/mL of human plasma, were incubated for 5, 30, and 60 min at 37 degrees C. Following incubation, the plasma was separated into its high-density (HDL), low-density (LDL), very-low-density (VLDL) lipoprotein and lipoprotein-deficient (LPDP) plasma fractions by density gradient ultracentrifugation. Each of these lipoprotein (LP) and LPDP fractions were analyzed for paclitaxel and plasma lipid levels by well-established HPLC and enzymatic assays. When TAX was incubated in human plasma for 5 min, an equal amount of drug was found in the LP and LPDP fractions. This distribution profile did not change following incubation for 30 and 60 min. Of the amount of TAX that was distributed within the LP fraction, 70-75% of TAX was associated with the HDL fraction for all time points studied. The paclitaxel plasma and LP distribution profile for PMT was similar to the distribution profile of TAX, suggesting that the plasma and LP distribution of paclitaxel is independent of the method of paclitaxel delivery and that LP distribution is not a function of mass lipid levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109049     DOI: 10.1021/js960333n

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  14 in total

1.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 2.  PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery.

Authors:  Hyunah Cho; Jieming Gao; Glen S Kwon
Journal:  J Control Release       Date:  2015-12-15       Impact factor: 9.776

Review 3.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

4.  Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)8-paclitaxel prodrug: In Vivo conversion and antitumor efficacy.

Authors:  Yu Tong Tam; Dae Hwan Shin; Karen E Chen; Glen S Kwon
Journal:  J Control Release       Date:  2019-02-18       Impact factor: 9.776

5.  Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Authors:  K M Wasan; P H Pritchard; M Ramaswamy; W Wong; E M Donnachie; L J Brunner
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

6.  Self-assembled poly(butadiene)-b-poly(ethylene oxide) polymersomes as paclitaxel carriers.

Authors:  Shuliang Li; Belinda Byrne; Joellen Welsh; Andre F Palmer
Journal:  Biotechnol Prog       Date:  2007 Jan-Feb

Review 7.  Micellar nanocarriers: pharmaceutical perspectives.

Authors:  V P Torchilin
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.200

8.  Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.

Authors:  Abeer M Al-Ghananeem; Ahmad H Malkawi; Yahya M Muammer; Justin M Balko; Esther P Black; Walid Mourad; Edward Romond
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

9.  Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors.

Authors:  Mohamed Nabil Khalid; Pierre Simard; Didier Hoarau; Alice Dragomir; Jean-Christophe Leroux
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

Review 10.  Nanoparticle-mediated drug delivery for treating melanoma.

Authors:  Vaibhav Mundra; Wei Li; Ram I Mahato
Journal:  Nanomedicine (Lond)       Date:  2015-08-05       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.